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Abstract 
The gut microbiome is now considered as a large organ that has a direct effect on gastrointestinal tract, immune 
and endocrine system. There is no evidence that gut microbiota regulates the immune system and is responsible 
for bone formation and destruction. Probiotics have been shown through the gastrointestinal tract to have a 
positive effect on the management of the healthy bone. This article discusses the latest data available from 
PubMed and Scopus databases regarding gut microbiome, probiotics and bone briefly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Gut microbiome (GM) is the largest one that 
includes trillions of bacteria, fungi and viruses that live 
in the intestinal tract. These bacteria have been found 
to modulate immune responses that are associated 
with many diseases such as Crohn’s, irritable bowel 
syndrome, celiac, cardiovascular, and rheumatic [1]. 
GM is a major regulator of bone mineral density via 
the effects of the immune system [2], [3]. It has been 
reported by several clinical trials the association of low 
intestinal bacteria and decreased bone mineral 
density [4]. There is no convincing evidence of the 
role of GM in the development of bone formation and 
destruction [4]. Very recently the importance of 
microbiome health has become now clear; many 
consider it as a new large organ, while specific strains 
have been identified to affect immune cells [5]. 
 
Review of Text 
 
Osteoporosis is a major public health burden 
in our ageing population [6]. Bone undergoes 
turnover continuously, and the immune system is 
regulating this process since 1980 [7]. This chronic 
progressive bone disease is mainly due to the 
natural cessation of endogenous estrogen marked 
by the onset of menopause and characterised by 
decreased bone mineral density (BMD) and negative 
changes in bone microarchitecture [8]. Estrogen 
cessation gives rise to two stages of bone loss: an 
early rapid loss of trabecular and cortical bone due to 
increased osteoclast activity and decreased 
osteoclast apoptosis, and a second slower prolonged 
loss due to decreased osteoblast activity [9]. This 
notable imbalance between bone formation and bone 
resorption increases the risk of fractures among 
postmenopausal women [10], [11]. Although estrogen 
therapy (ET) was shown effective in the prevention 
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and treatment of estrogen-deficient osteoporosis in 
postmenopausal women, its use remains 
controversial due to its association with increased risk 
of breast, endometrium and ovaries cancer [12]. 
Recently, alternative and complementary 
therapies such as dietary supplements have become 
the preferred prophylactic treatment of clinicians and 
patients in the prevention and management of 
osteopenia [13]. Meta-analyses have shown that daily 
intake of 1200 mg Calcium (Ca) and 20–25 mg 
vitamin D (D) can reduce total- and hip-fracture risk by 
15% and 30%, respectively, [14], hence, it seems that 
C a  a n d  D  supplementation alone is not sufﬁcient 
to fully prevent the menopausal bone loss.  
In the past decade, a growing body of 
evidence suggests that probiotics may have 
favourable effects on bone health. Probiotics are 
living microorganisms that could influence the GM 
composition and exert positive effects that have been 
attributed to several complex mechanisms, including 
enhanced mineral absorption, beneficial anti-
inﬂammatory pathways [15] and many more. 
Probiotic strains differ signiﬁcantly in genotype and 
phenotype, and they may show different metabolic 
functions, particularly with regards to immune 
function [16].  
In earlier reports, various strains of 
Lactobacillus and Biﬁdobacterium were shown to 
prevent and even restore bone loss related to 
estrogen deﬁciency [17], they were also shown to 
cause a 45% increase in femoral and vertebral 
trabecular bone volume fraction in mice [18]. More 
recently, a randomized, double-blind, placebo-
controlled study [19] revealed that multispecies 
probiotic supplementation (7 speciﬁc strains: 
Lactobacillus casei,  Biﬁdobacterium longum, 
Lactobacillus acidophilus, Lactobacillus rhamnosus, 
Lactobacillus bulgaricus, Biﬁdobacterium breve and 
Streptococcus thermophiles)  among postmenopausal 
osteopenic women diminished bone resorption 
through significant effects on serum concentrations of 
bone biomarkers, such as serum bone-specific alkaline 
phosphatase (s-BALP) and serum C-terminal 
telopeptide of type I collagen (CTX). Decreased 
serum levels of BALP, the marker of bone turnover 
and CTX-produced by osteoclasts during the bone 
resorption process- compared to the placebo group, 
suggest a protective effect of this multispecies 
probiotic against bone resorption. These results are 
consistent with earlier studies using Biﬁdobacterium 
subtilis (CH201) [20], Biﬁdobacterium longum [21] and 
Lactobacillus reuteri [22]. 
The beneficial effects of probiotics on nutrients 
absorption were highlighted in several recent reports. 
Various strains of Lactobacillus and Bifidobacteria were 
shown to influence the pH of the gut and the 
metabolism of bile acids [23], important factors in the 
control of nutrients absorption, especially calcium. 
Lactobacillus helveticus fermented milk exhibited an 
acute positive effect on calcium metabolism. Thus, in 
addition to the well-established benefits of calcium 
and vitamin D content of milk, it is possible that some 
types of probiotics may aid in the breakdown of 
proteins contained in milk to biologically active 
peptides [24]. Furthermore, elevated concentration of 
Lactobacillus reuteri and Bifidobacterium longum in 
the gut may be involved in promoting mineral (calcium, 
magnesium, and phosphate) absorption resulting in an 
increased BMD. Probiotics were also shown to play 
an essential role in the synthesis of vitamin B and 
vitamin K, which are critical for the regulation of bone 
health [25]. 
On another  note,  various strains of 
probiotics were shown to affect bone health via the 
production of short-chain fatty acids (SCFA). SCFA 
are byproducts produced by the microbiota during 
fermentation of dietary fibre and were reported to have 
direct effects on osteoclasts and osteoblasts. For 
example, butyrate is an SCFA known to reduce 
osteoclastogenesis by suppressing the receptor 
activator for nuclear factor κB ligand signalling 
pathway [26]. More recently, SCFA were shown to 
have indirect effects on endocrine factors such as 
peptide YY and glucagon-like peptide 1 Peptide YY is 
a gastrointestinal hormone secreted from the 
endocrine L cells and is negatively associated with the 
total body and hip BMD in premenopausal women 
[27]. Glucagon-like peptide 1, an amino acid hormone 
that is also secreted from the endocrine L cells, has 
been shown to act as a regulator of bone metabolism 
by altering the balance between osteoblast and 
adipocyte differentiation from bone mesenchymal stem 
cells [28]. 
When it comes to the immune-modulatory 
properties, probiotic administration was shown to 
reduce the expression of several pro-inﬂammatory 
and osteolytic cytokines such as Tumor Necrosis 
Factor-α (TNF -α) and Interleukin-1b (IL-1b) [29]. 
Lactobacillus reuteri, Lactobacillus rhamnosus and 
Lactobacillus paracasei [30] were shown to decrease 
osteoclastogenesis and bone resorption significantly. 
Lactobacillus reuteri enhanced the suppression of pro-
inﬂammatory cytokines TNF-mediated bone 
resorption in mice [19] and enhanced the reduction of 
the percentage of CD4C T cells in bone marrow 
[22]. The treatment was able to improve bone health 
in healthy male mice [19]. Similarly, decreased TNF-
α and IL-1b, along with increased anti-inﬂammatory 
cytokine IL-10 also resulted from oral administration 
of Saccharomyces cerevisiae [31]. 
One of the recent applications of 
probiotics is the incorporation of Bacillus spp. in 
birds’ feeds to promote growth, as an alternative to 
the harmful antibiotic growth promoters (AGP). 
Several studies show that certain strains of Bacillus 
subtilis also promote the growth of chickens to a 
greater extent than AGP [32].  
On the other hand, it is important to note 
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that, in contrast with the reported benefits of 
probiotics on bone health, a recent study [6] 
showed that dietary enrichment with powdered 
whole grape and probiotics (composed of equal 
parts Bifidobacterium bifidum, B. breve, Lactobacillus 
casei, L. plantarum, and L. bulgaricus) exerted either 
no effect on bone microarchitecture in a mouse 
model of age-related osteoporosis. However, this 
negative effect was attributed to possible differences 
in probiotic strains, the small sample size and the 
duration of the supplementation.  
 
 
Conclusions 
 
Current research efforts, although varied, 
mostly indicate favourable effects of probiotics on 
bone metabolism. Therefore, long-term investigations 
with different strains of probiotics are needed to dissect 
the mechanisms and effects on bone formation and 
resorption, especially in humans. 
This relationship is a promising area of 
investigation, which potential outcomes could lead to 
physicians directing their therapeutic efforts to 
probiotics, among dietary supplements, for most 
effective treatments for bone-related ailments.  
Future directions are focused now on the 
major role of the gut microbiome in rheumatic 
disease, and a lot of interest is growing in the gut 
microbiome manipulation as a therapeutic tool for 
bone diseases. Preclinical models may also be a 
future promise for the treatment of bone disease. 
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